KalVista Pharmaceuticals (KALV) Interest Expenses (2014 - 2025)

KalVista Pharmaceuticals (KALV) has 12 years of Interest Expenses data on file, last reported at $3.5 million in Q3 2025.

• For the quarter ending Q3 2025, Interest Expenses fell 53.71% year-over-year to $3.5 million; the trailing twelve-month figure through Jul 2025 stood at $3.9 million (down 49.14% YoY), and the FY2025 full-year result was $65.1 million, up 2496.33% from the prior year.
• Interest Expenses improved to $3.5 million in Q3 2025, from $2000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $28.2 million in Q2 2022 to a low of $2000.0 in Q4 2024.
• A 5-year average of $8.0 million and a median of $9.3 million in 2024 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses plunged 80.95% in 2021 and soared 10709.2% in 2022, its largest moves.
• Tracing KALV's Interest Expenses over 5 years: stood at $9.5 million in 2021, then advanced by 20.56% to $11.4 million in 2022, then slipped by 15.13% to $9.7 million in 2023, then tumbled by 99.98% to $2000.0 in 2024, then jumped by 176000.0% to $3.5 million in 2025.
• Business Quant data shows KALV's Interest Expenses at $3.5 million in Q3 2025, $2000.0 in Q4 2024, and $6.9 million in Q4 2024.